Marshall Wace, LLP Fate Therapeutics Inc Transaction History

Marshall Wace, LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$3.26 - $7.08 $50,057 - $108,713	-15,355 Reduced 4.45%	330,082 $1.08 Million
Q1 2024 May 15, 2024	BUY	$3.54 - $8.35 $1.22 Million - $2.88 Million	345,437 New	345,437 $2.54 Million
Q1 2022 May 16, 2022	SELL	$29.67 - $60.28 $2.21 Million - $4.5 Million	-74,622 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $4.96 Million - $6.67 Million	-103,716 Reduced 58.16%	74,622 $4.37 Million
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $7.54 Million - $12.2 Million	127,195 Added 248.7%	178,338 $10.6 Million
Q2 2021 Aug 13, 2021	BUY	$67.25 - $92.52 $3.44 Million - $4.73 Million	51,143 New	51,143 $4.44 Million
Q1 2021 May 17, 2021	SELL	$72.16 - $117.4 $4.93 Million - $8.02 Million	-68,278 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$38.09 - $100.95 $2.6 Million - $6.89 Million	68,278 New	68,278 $6.21 Million
Q1 2020 May 15, 2020	SELL	$17.28 - $31.88 $281,197 - $518,783	-16,273 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$13.39 - $20.73 $217,895 - $337,339	16,273 New	16,273 $318,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.